price month
addit thought morn
bottom line follow initi quick take multipl bristol headlin
morn provid addit thought topic
miss primari endpoint hepatocellular market
rel small one patient us global one
bristol seem well posit time perspect
trial show trend toward overal surviv benefit lack statist
signific open door competitor merck roch astra
becom domin player indic variou
combin trial current run
otezla divest surpris bristol divest otezla
order address concern rais ftc allow celgen
deal close time manner like otezla bristol key intern pipelin
asset phase oral inhibitor also
develop psoriasi howev given competit psoriasi
market drug differ mechan action expect
ftc concern overlap otezla admittedli one
core product bristol/celgen deal still grow asset
assum sale would
provid nice commerci synergi bristol prepar
launch year key otezla
bristol obtain asset believ seller often
disadvantag potenti buyer know need divest given asset
mani compani drug dermatolog space may
look bid asset coverag alon believ
lilli may interest assum see regulatori concern
otezla would fit portfolio pharmavalu databas
suggest npv drug
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
celgen deal close push previous note believ
mani investor intrigu bristol stori especi given stock current
valuat howev also believ investor wait
data lung cancer pass wait celgen deal get closer
close get name result like rais
question look deal close get push end
may keep potenti investor sidelin longer
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
revenu
market sell administr
equiti net incom affili
allianc licens incom
total incom expens
provis incom tax
net incom dilut ep
ms sale
revenu
ep continu oper
revenu
market sell administr
amort acquir intang celg
equiti net incom affili
allianc licens incom
amort approv mileston celgen
total incom expens
provis incom tax
net incom dilut ep
ms sale
revenu
ep continu oper
charl martineau univers toronto compani mention price
